Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia.

6533b85cfe1ef96bd12bd398

RESEARCH PRODUCT

Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia.

Maurizio Averna Claudio Bilato Giorgio Sesti On Behalf Of The Italian Clinical Network On Bempedoic Acid Daniele Andreini Enzo Bonora Gianluca Campo Roberto Catalini Matteo Marco Ciccone Salvatore De Rosa Carlo Di Mario Claudio Ferri Nicola Ferri Liliana Grigore Antonio Lanzilli Giuseppe Mandraffino Tiziana Montalcini Federico Nardi Matteo Pirro Roberto Pontremoli Francesco Prati Francesco Purrello Vincenzo Russo Tiziana Sampietro Riccardo Sarzani Marino Scherillo Roberto Scicali Patrizia Suppressa Pierluigi Temporelli Pierfrancesco Terrosu Maurizio Tespili Roberto Trevisan

subject

ATP citrate lyase Endocrinology Diabetes and Metabolism Medicine (miscellaneous)Hyperlipidemias Pharmacology Lipid-lowering therapy Lipid-lowering treatment Medicine LDL-cholesterol Humans Dicarboxylic Acids Hypolipidemic Agents Ldl cholesterol Nutrition and Dietetics Lipid management business.industry Novel LDL-C treatment.Fatty Acids Cholesterol LDL Bempedoic acid Novel LDL-C treatment ATP citrate lyase ATP citrate lyase; bempedoic acid; LDL-cholesterol; lipid-lowering treatment; novel LDL-C treatment Lipid lowering Cardiology and Cardiovascular Medicine business Clinical evaluation Bempedoic acid

description

Bempedoic acid (BA) is a novel first-in-class oral lipid-lowering therapy. BA has been approved by the European Medicinal Agency and Food and Drug Administration and has been commercialised throughout Europe since the end of 2020 as an add-on therapy in patients at high/very-high cardiovascular risk that are not at LDL-C goals with current lipid-lowering treatments. Recently, Italian lipid management experts gathered to discuss several open questions on BA characteristics and BArelated practical clinical issues. The panel permitted collection of its opinions in a ten Q&A format. Aim: The aim of this viewpoint is to discuss and answer several open questions on BA characteristics and BA-related practical clinical issues. Data synthesis: The data includes main phase III studies, subanalysis and meta-analysis on BA. Conclusions: The panel permitted collection of its opinions in a ten Q&A format.

year	journal	country	edition	language
2021-07-05	Nutrition, metabolism, and cardiovascular diseases : NMCD

10.1016/j.numecd.2021.09.023 https://pubmed.ncbi.nlm.nih.gov/34802854